RCAG
NVO

Rehmann Capital Advisory Group’s Novo Nordisk NVO Stock Holding History

Rehmann Capital Advisory Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$595K Sell
16,188
-2,364
-13% -$112K 0.03% 355
2025
Q4 		$944K Buy
18,552
+4,664
+34% +$239K 0.05% 250
2025
Q3 		$771K Buy
13,888
+702
+5% +$41.1K 0.04% 283
2025
Q2 		$910K Sell
13,186
-961
-7% -$65.4K 0.06% 231
2025
Q1 		$982K Sell
14,147
-113
-0.8% -$9.33K 0.06% 223
2024
Q4 		$1.23M Buy
14,260
+415
+3% +$44.9K 0.08% 186
2024
Q3 		$1.65M Sell
13,845
-316
-2% -$42.1K 0.11% 145
2024
Q2 		$2.02M Sell
14,161
-437
-3% -$57.9K 0.14% 121
2024
Q1 		$1.87M Sell
14,598
-454
-3% -$54K 0.14% 121
2023
Q4 		$1.56M Sell
15,052
-39
-0.3% -$3.86K 0.13% 130
2023
Q3 		$1.37M Sell
15,091
-1,283
-8% -$113K 0.13% 126
2023
Q2 		$1.32M Sell
16,374
-278
-2% -$22.7K 0.12% 139
2023
Q1 		$1.33M Sell
16,652
-640
-4% -$45.4K 0.12% 140
2022
Q4 		$1.17M Sell
17,292
-1,058
-6% -$62K 0.12% 151
2022
Q3 		$914K Sell
18,350
-342
-2% -$18.3K 0.1% 174
2022
Q2 		$1.04M Buy
18,692
+838
+5% +$46.5K 0.11% 157
2022
Q1 		$994K Buy
17,854
+1,208
+7% +$62K 0.09% 190
2021
Q4 		$932K Sell
16,646
-1,012
-6% -$54.8K 0.09% 201
2021
Q3 		$848K Sell
17,658
-44
-0.2% -$2.13K 0.08% 214
2021
Q2 		$744K Buy
17,702
+112
+0.6% +$4.34K 0.07% 233
2021
Q1 		$593K Buy
17,590
+22
+0.1% +$784 0.06% 251
2020
Q4 		$614K Sell
17,568
-68
-0.4% -$2.35K 0.07% 229
2020
Q3 		$612K Sell
17,636
-300
-2% -$10K 0.08% 217
2020
Q2 		$587K Sell
17,936
-1,010
-5% -$32.2K 0.08% 211
2020
Q1 		$570K Buy
+18,946
New +$564K 0.09% 180
2019
Q3 		$61.3K Sell
2,372
-8
-0.3% -$202 0.01% 569
2019
Q2 		$60.8K Buy
2,380
+510
+27% +$12.6K 0.01% 767
2019
Q1 		$48.9K Buy
1,870
+254
+16% +$6.24K 0.01% 818
2018
Q4 		$37.2K Buy
1,616
+36
+2% +$800 0.01% 684
2018
Q3 		$37.2K Sell
1,580
-2
-0.1% -$49 0.01% 913
2018
Q2 		$36.5K Sell
1,582
-594
-27% -$14.1K 0.01% 889
2018
Q1 		$54K Buy
+2,176
New +$57.1K 0.01% 738

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Rehmann Capital Advisory Group's NVO Position: Q1 2026 in Review

Rehmann Capital Advisory Group reduced its Novo Nordisk (NVO) stake by 13% in Q1 2026, selling an estimated $112K and leaving 16,188 shares worth $595K. The position accounts for 0.03% of the portfolio, ranked #355.

Rehmann Capital Advisory Group first reported a position in NVO in Q1 2018 and has held it in 32 quarters since. The position peaked at $2.02M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Rehmann Capital Advisory Group held 16,188 shares of Novo Nordisk worth $595K as of Q1 2026.
  • Rehmann Capital Advisory Group sold 2,364 Novo Nordisk shares in Q1 2026, an estimated $112K.
  • Novo Nordisk made up 0.03% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #355 holding.
  • Rehmann Capital Advisory Group first reported a position in Novo Nordisk in Q1 2018 and has held it in 32 quarters since.
  • Rehmann Capital Advisory Group's Novo Nordisk position peaked at $2.02M in Q2 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.